Phase IIa Multicentre Study Investigating of VR040 in Parkinson's Disease
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
'Off periods' where people with Parkinson's disease are slow, stiff and unable to function
are disabling, and a treatment which can converts people to a "on", good, able to function
state would be extremely useful. We assessed safety, tolerability and efficacy of inhaled dry
powder apomorphine (VR040) in a clinic-based study in this setting.